Intralesional or intraorbital rituximab injection for the management of biopsy-proven idiopathic orbital inflammation involving the lacrimal gland

CONCLUSION: Intralesional rituximab injection may be an effective treatment for IOI involving the lacrimal gland, achieving a 78% complete response rate in this series. Local treatment with rituximab has the potential to avoid the ocular and systemic side effects of corticosteroid and systemic immunosuppressive treatment.PMID:37995759 | DOI:10.1016/j.jcjo.2023.10.016

Source: Canadian Journal of Ophthalmology - November 23, 2023 Category: Opthalmology Authors: Hakan Demirci Suleyman Ciftci Honeylen M Tiu Teo F Yesim Demirci Roman Shinder Victor M Elner Source Type: research